Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05260541 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder
A Phase 2 study, sponsored by Praxis Precision Medicines.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT05260541 is a Phase 2 study that was terminated before completion, run by Praxis Precision Medicines. The registered enrollment target is 11 participants.
The verdict
NCT05260541, a Phase 2 study, was terminated before completion, sponsored by Praxis Precision Medicines.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This trial is comprised of a 4-week randomized, double-blind, placebo-controlled treatment period followed by an optional 8-week open-label extension (OLE) period. This trial will evaluate the efficacy and safety of oral PRAX-114 flexibly dosed at 40 to 60 mg for 4 weeks compared to placebo in adults with PTSD. The OLE period consisting of treatment with 40 mg PRAX-114 for 8 weeks will provide additional efficacy and safety data.
Interventions
- DRUG Placebo
- DRUG 40 mg PRAX-114
- DRUG 60 mg PRAX-114 or 40 mg PRAX-114
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2022-01-25 |
| Est. Completion | 2022-09-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05260541
The ClinicalTrials.gov registry entry for NCT05260541 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Praxis Precision Medicines, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05260541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05260541 about?
NCT05260541 is a clinical study titled "A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder". This trial is comprised of a 4-week randomized, double-blind, placebo-controlled treatment period followed by an optional 8-week open-label extension (OLE) period. This trial will evaluate the efficacy and safety of oral PRAX-114 flexibly dosed at 40 to 60 mg for 4 weeks compared to placebo in adul...
What is the current status of trial NCT05260541?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2022-01-25. Estimated completion is 2022-09-23.
What interventions are being tested in trial NCT05260541?
The interventions under investigation include: Placebo (DRUG), 40 mg PRAX-114 (DRUG), 60 mg PRAX-114 or 40 mg PRAX-114 (DRUG).
Who is sponsoring clinical trial NCT05260541?
This trial is sponsored by Praxis Precision Medicines, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.